Onyx Scientific, Cancer Research UK To Partner On Range of Projects
By Lori Clapper
Contract manufacturer Onyx Scientific is now managing a range of Cancer Research UK’s drug development projects, including the development and manufacturing of active pharmaceutical ingredients (API) for use in clinical trials.
Cancer Research UK plans to utilize the CMO’s expertise in process development, solid-state chemistry, as well as analytical and GMP synthesis of API. To assist, IPCA Laboratories-owned Onyx Scientific can utilize MHRA and FDA inspected facilities in the UK and India. The company supports companies with medicinal chemistry and preclinical development through Phase I to III, scaling-up to large scale API production.
Cancer Research UK’s Drug Development Office first selected the Onyx for a GMP synthesis project in 2011 and has since partnered for several successful campaigns. In fact, Onyx Scientific is one of the Charity’s preferred providers for API development and GMP synthesis.
“Over the last few years, the team at Onyx Scientific has worked proactively with us on several challenging synthetic chemistry projects and provided exceptional value for money, which has led to us to select them for several new projects based on their competitive costs and ability to delivery on time,” Dr. Nigel Westwood, drug supply manager at Cancer Research UK, said.
Westwood also stressed the importance in having “sufficient quantities of API available in a timely manner” to keep up with the organization’s drug development research. Onyx will back that effort through delivering early stage programs and providing effective scale up, tech transfer, and overall project efficiency.
“It is very pleasing that our track-record and reputation in solid state chemistry and GMP API manufacturing continues to grow,” Denise Bowser, commercial director at Onyx Scientific, said. “This has led to us to work with several of the biggest pharmaceutical companies in the world alongside many smaller drug developers and charitable bodies.”